SLXN

Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Silexion Therapeutics Corp revenue for the last quarter amounts to -3.29M USD, decreased -59.03 % YoY.

Silexion Therapeutics Corp. EPS for the last quarter amounts to -2843000.00 USD, increased 6.52 % YoY.

Silexion Therapeutics Corp (SLXN) has 11 emplpoyees as of January 10 2026.

Today SLXN has the market capitalization of 6.63M USD.